International Journal of Cancer · 2002 · 43 citations · 17 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyDna RepairAlkylating AgentsDose Adjustment In OncologyDose SchedulingMalignant NeoplasmsMelanoma PharmacotherapyPharmacodynamics Of Anticancer Agents6-Thioguanine TherapyAnimal Disease ModelsO6-alkylguanine RepairRepair Of O6-alkylguanine LesionsRodent Tumor ModelsTemozolomide TherapyTherapeutic Index Determination
The DNA repair protein O(6)-alkylguanine DNA alkyltransferase (ATase) is a major component of resistance to treatment with methylating agents and nitrosoureas. Inactivation of the protein, via the administration of pseudosubstrates, prior to chemotherapy has been shown to improve the latter's therapeutic index in animal models of human tumours. We have also shown that rational scheduling of temozolomide, so that drug is administered at the ATase nadir after the preceding dose, increases tumour growth delay in these models. We now report the results of combining these two approaches. Nude mice bearing A375M human melanoma xenografts were treated with vehicle or 100 mg/kg temozolomide ip for 5 doses spaced 4, 12 or 24 hr apart. Each dose was preceded by the injection of vehicle or 20 mg/kg 4BTG. All treatments resulted in significant delays in tumour quintupling time compared with controls: by 6.2, 5.9 and 16.8 days, respectively, for 24-, 12- and 4-hourly temozolomide alone and by 22.3, 21.3 and 22.1 days, respectively, in combination with 4BTG. Weight loss due to TMZ was unaffected by the presence of 4BTG. This was of the order of 6.2-10.6% with 24- and 12-hourly administration and 17.4-20.1% (p < 0.0001) with 4-hourly treatment. In our model, combining daily temozolomide with 4-BTG confers increased antitumour activity equivalent to that achieved by compressing the temozolomide schedule but with less toxicity. Using temozolomide schedule compression with 4-BTG does not improve on this result, suggesting that ATase inactivation with pseudosubstrates is a more promising means of enhancing the activity of temozolomide than compressed scheduling.
17
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
Marı́a S. Soengas, Paola Capodieci, David Polsky et al. · Nature · 2001 · 959 citations
Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage
P Branch, Gabriele Aquilina, Margherita Bignami et al. · Nature · 1993 · 358 citations
Phase I trial of temozolomide using an extended continuous oral schedule.
C. Brock, E.S. Newlands, Stephen R. Wedge et al. · PubMed · 1998 · 284 citations
Medicine, Oncology, Pharmacology +17